LI Peng, YIN Jingjing, ZHOU Wenhua, GAO Jie, GONG Jiage, ZHANG Mengdan, LI Jianguo. Research Progress of 161Tb Labelled Radiopharmaceuticals[J]. Journal of Isotopes, 2022, 35(6): 550-557. DOI: 10.7538/tws.2022.youxian.031
Citation: LI Peng, YIN Jingjing, ZHOU Wenhua, GAO Jie, GONG Jiage, ZHANG Mengdan, LI Jianguo. Research Progress of 161Tb Labelled Radiopharmaceuticals[J]. Journal of Isotopes, 2022, 35(6): 550-557. DOI: 10.7538/tws.2022.youxian.031

Research Progress of 161Tb Labelled Radiopharmaceuticals

  • The radiolanthanide 161Tb has garnered increasing interest due to its favorable properties for medical application.161Tb showed similar properties to the widely used therapeutic radionuclide 177Lu, and had better curative effect, which was expected to replace 177Lu as a new type of therapeutic radionuclide. So far, the studies on the application of 161Tb have mainly focused on the basic in vivo behavior of 161Tb-labeled biomolecules and their effects on malignant tumors compared with 177Lu. These preliminary therapeutic studies show that 161Tb was more effective than 177Lu in tumor treatment if the same activity was used. The characteristics, production and research progress of labeled radiopharmaceuticals of 161Tb are reviewed, which can provide reference for the development and clinical application of therapeutic radionuclides.
  • loading

Catalog

    Turn off MathJax
    Article Contents

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return